Processing

Please wait...

Settings

Settings

Goto Application

1. WO2014166971 - PROGESTERONE RECEPTOR ANTAGONIST DOSAGE FORM

Publication Number WO/2014/166971
Publication Date 16.10.2014
International Application No. PCT/EP2014/057101
International Filing Date 09.04.2014
IPC
A61K 31/567 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
565not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
567substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61P 15/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders; Contraceptives
CPC
A61K 31/567
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
565not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
567substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 9/0053
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0053Mouth and digestive tract, i.e. intraoral and peroral administration
A61K 9/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
A61P 15/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders
A61P 15/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders
08for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • BAYER PHARMA AKTIENGESELLSCHAFT [DE]/[DE]
Inventors
  • SCHÜTT, Barbara
  • SCHULTZE-MOSGAU, Marcus-Hillert
  • KAISER, Andreas
Agents
  • BIP PATENTS
Priority Data
13163417.211.04.2013EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PROGESTERONE RECEPTOR ANTAGONIST DOSAGE FORM
(FR) FORME POSOLOGIQUE DE L'ANTAGONISTE DU RÉCEPTEUR DE LA PROGESTÉRONE
Abstract
(EN)
The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11 β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one at the dosage of about 0.5 to 5 mg and more particularly 2 mg. Additionally, the invention is directed to the use of the novel pharmaceutical composition for treatment of and/or prophylaxis of gynaecological diseases, such as fibroids of the uterus (myomas, uterine leiomyoma), endometriosis or excessive menstrual bleeds, and method for obtaining such composition and oral dosage form.
(FR)
La présente invention concerne une composition pharmaceutique comprenant un antagoniste du récepteur de la progestérone à savoir (11 β,17β)-17-Hydroxy-11-[4-(méthylsulphonyl)phényle]-17-(pentafluoroéthyl)estra-4,9-dien-3-un dont la posologie est de 0,5 à 5 mg environ et plus particulièrement 2 mg. De plus, l'invention concerne l'utilisation d'une nouvelle composition pharmaceutique destinée au traitement et à la prophylaxie des maladies gynécologiques comme les fibroïdes utérins (myomes, fibrome utérin), l'endométriose ou les saignements menstruels excessifs et un procédé permettant d'obtenir cette composition et une forme posologique orale.
Latest bibliographic data on file with the International Bureau